Lokich J J, Frei E, Jaffe N, Tullis J
Cancer. 1976 Aug;38(2):667-71. doi: 10.1002/1097-0142(197608)38:2<667::aid-cncr2820380207>3.0.co;2-1.
B-DOPA (Bleomycin (B), D-imidazole carboxamide (D), Oncovin (O), Prednisone (P), Adriamycin (A) is a program developed for the treatment of Hodgkin's disease resistant to MOPP therapy. Twenty unselected patients were treated by the following dose schedule: B, 4 mg/m2 days 2 and 5; D, 150 mg/m2 days 1 to 5; O (vincristine), 1.5 mg/m2 days 1 and 5; P, 40 mg/m2 days 1 to 6; A, 60 mg/m2 day 1. Each course, was repeated at 3 to 4 week intervals to maximum adriamycin dose of 450 mg/m2. All patients had received prior MOPP therapy and six had received prior radiotherapy. Fifteen of the 20 patients entered into the study were evaluable for response. There were nine (60%) complete responders and three (20%) partial responders. The median duration of complete remission was 14+ months with six of nine patients remaining in remission to a maximum of 21 months. The median survival of the nonresponders was 3 months. B-DOPA is an effective combination chemotherapy regimen for advanced Hodgkin's disease in patients who have previously received MOPP treatment, including patients who are refractory to MOPP therapy. The B-DOPA program or modifications thereof, may be integrated into primary treatment programs for advanced Hodgkin's disease.
B-DOPA方案（博来霉素（B）、D-咪唑甲酰胺（D）、长春新碱（O）、泼尼松（P）、阿霉素（A））是为治疗对MOPP疗法耐药的霍奇金病而制定的方案。20例未经挑选的患者按以下剂量方案接受治疗：博来霉素，4mg/m²，第2天和第5天；D-咪唑甲酰胺，150mg/m²，第1天至第5天；长春新碱，1.5mg/m²，第1天和第5天；泼尼松，40mg/m²，第1天至第6天；阿霉素，60mg/m²，第1天。每个疗程每隔3至4周重复一次，阿霉素最大剂量为450mg/m²。所有患者此前均接受过MOPP疗法，6例曾接受过放疗。参与该研究的20例患者中有15例可评估疗效。有9例（60%）完全缓解者和3例（20%）部分缓解者。完全缓解的中位持续时间为14 +个月，9例患者中有6例持续缓解，最长达21个月。未缓解者的中位生存期为3个月。B-DOPA是一种有效的联合化疗方案，适用于此前接受过MOPP治疗的晚期霍奇金病患者，包括对MOPP疗法耐药的患者。B-DOPA方案或其改良方案可纳入晚期霍奇金病的初始治疗方案。
